Original Article

Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis

Linxuan Wei¹, Xiaolin Liu¹, Wenjing Zhang¹, Yuyan Wei¹, Yingwei Li¹, Qing Zhang¹, Ruifen Dong¹, Jungeun Sarah Kwon⁴, Zhaojian Liu², Wenxin Zheng¹,³,⁵,⁶, Beihua Kong⁶

¹Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China; ²Department of Cell Biology, Shandong University School of Medicine, Jinan, Shandong, China; ³Department of Pathology, University of Arizona College of Medicine, AZ, USA; ⁴Department of Molecular and Cellular Biology, University of Arizona, Tucson, Arizona, USA; ⁵Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; ⁶Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA

Received January 10, 2016; Accepted January 14, 2016; Epub January 15, 2016; Published February 1, 2016

Abstract: The high-mobility group A protein 2 (HMGA2) is a non-histone chromatin factor highly expressed in fetal tissue and malignant tumors but rarely detected within normal adult tissues. The clinical implications and biological functions of HMGA2 in endometrial carcinoma are largely unknown. Here we report that HMGA2 expression was barely detected in benign endometrium samples (2 of 28 samples). However, HMGA2 expression increased significantly from precancerous lesion endometrial glandular dysplasia (7 of 17, 41.2%), to serous endometrial intraepithelial carcinoma (5 of 8, 62.5%) and to full blown endometrial serous carcinoma (39 of 59, 66.1%). Functional characterization of HMGA2 revealed that the gene has both tumor growth promotion and metastasis. In addition, HMGA2 induced epithelial-mesenchymal transition (EMT) through modulation vimentin and β-catenin. Furthermore, HMGA2 overexpression started from endometrial serous precancers, non-invasive cancers, as well as in full blown carcinomas in a p53 knockout mouse model we recently established in our laboratory. Our findings suggest that HMGA2 may serve as a useful diagnostic marker in the assessment of endometrial serous cancer and its precursor lesions.

Keywords: HMGA2, endometrial serous carcinoma, tumor growth, metastasis, EMT

Introduction

Endometrial carcinoma is the most common gynecologic malignancy, which has been classified into two different types, based on clinical, pathological and epidemiological observations [1, 2]. The rarer yet more clinically aggressive cancer, endometrial serous carcinoma (ESC) accounts for approximately 10-15% of all endometrial cancers but is responsible for a disproportionate 40% of the cancer related death [3]. Despite the significant advances about the carcinogenesis of type I cancer (mainly endometrioid type), progresses about type II carcinogenesis, particularly the development of ESC, is significantly lacking. Therefore, the importance of understanding endometrial serous carcinogenesis is highly needed.

High-mobility group A2 (HMGA2), a member of the high-mobility group family, is a non-histone nuclear-binding oncofetal protein, which can modulate transcription by promoting conformational changes [4]. HMGA2 is highly expressed in embryonic tissue and in many malignant neoplasms including the pancreas [5], thyroid [6], lung [7], and ovary [8], but rare in normal adult tissues [9]. There is strong evidence from previous studies that expression of HMGA2 is associated with tumor aggressive behavior, which is probably due to its biologic function related to epithelial-mesenchymal transition [10] and stem cell self-renewal ability [11].

Previous studies have shown that the overexpression of HMGA2 was a critical molecular event responsible for the tumorigenesis of ovarian serous cancers [12, 13]. A recent study demonstrated that HMGA2 was also overexpressed in advanced endometrial cancers by immunohistochemistry [14]. However, whether HMGA2 plays an oncogenic role in the develop-
HMGA2 in endometrial serous carcinogenesis

The role of HMGA2 in ESC remains unclear. The goal of this study was to explore the role of HMGA2 in ESC. For the first time, we have revealed that HMGA2 overexpression started from endometrial serous precancer, to serous endometrial intraepithelial carcinoma, and to full blown ESCs and it was intimately linked to P53 gene dysfunction in ESCs.

Materials and methods

Case selection

All evaluated endometrial samples were derived from Departments of Pathology at Yale University and the University of Arizona after obtaining an Institutional Review Board approval. Total of 173 endometrial samples were studied which included benign endometrium (n=28), endometrial glandular dysplasia (EmGD) (n=17), endometrial intraepithelial carcinoma (EIC) (n=8), endometrial serous carcinoma (ESC) (n=59) and endometrial endometrioid carcinoma (EEC) (n=61). All malignant cases were diagnosed using criteria of the International Federation of Gynecology and Obstetrics (FIGO). EmGD was diagnosed as defined by Zheng et al. [15]. All the benign endometrium come from age-matched hysteromyoma patients had hysterectomy or ovarian cancer with normal endometrium.

Cell lines and cell culture

KLE, HEC-1-A and AN3 CA were purchased from the American Type Culture Collection (ATCC). Ishikawa and SPEC-2 cell lines were generously provided by Dr. Wenxin Zheng (The University of Arizona, Tucson, AZ, USA). HEK293T was purchased from China Type Culture Collection (Shanghai, China). HEC-1-A cell line was maintained in McCoy’s 5A modified medium, KLE cell line was maintained in DMEM:F12 medium, AN3 CA and SPEC-2 cell lines were cultured in Eagle’s minimum essential medium, Ishikawa and HEK293T were culture in DMEM. All cell culture media were supplemented with 10% fetal bovine serum (FBS) and culture media for SPEC-2 cells were also supplemented with 100 mM sodium pyruvate. All cell lines were cultured and maintained in 5% CO₂ at 37°C.

Plasmids and transfection

HMGA2 overexpression plasmid pBABE-puro-HMGA2 was kindly provided by Dr. Jianjun Wei (Northwest University, Chicago, IL, USA). Retrovirus-pBABE-puro-HMGA2 and the control retrovirus-pBABE-puro were produced in GPZ-293 package cells. All the constructs were validated by sequencing. For stable infection, cells (1×10⁵) were plated in six-well plates without antibiotics for 1 day before incubation. Then, the medium was replaced with 1 mL of retrovirus solution generated from the step mentioned above. The solution was supplement with 10 µg/mL polybrene. After 24 h period, fresh medium containing 2 µg/mL puromycin (Sigma-Aldrich) was added to each well. Multiple colonies were obtained after 2 weeks of puromycin selection.

Transient transfection

HMGA2 siRNAs and control siRNA (Sigma-Aldrich) were used for transfecting endometrial cancer cells with lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s protocol. The efficiency of HMGA2 inhibition was assessed by western blot.

Migration and invasion assays

For cell migration assay, endometrial cancer cells (5-10×10⁴ cells) were seeded into the upper chambers of a transwell system (24-well, 8 µm pore size, BD falcon) with 200 µl of media containing no FBS. The lower chambers were filled with 500 µl culture media containing 10% FBS as a chemotactrant. After 24-32 hours, cells in the lower surface of the membrane were fixed in methanol for 15 minutes, stained with 0.1% crystal violet for 30 minutes. After removing the noninvading cells with a cotton swab, the successfully invading cells were counted under a light microscope. Invasion assays were performed using Matrigel-coated transwell system according to the manufacturer’s protocol. The incubation time was 48 hours.

Western blotting

Cultured cells were harvested and lysed in lysis buffer. The protein concentration was determined by BCA Assay Kit (Thermo Scientific). Cell lysates were separated by SDS-PAGE and transferred to PVDF membrane (Millipore). After blocking with 5% non-fat milk, the membranes were incubated with primary antibody and corresponding horseradish peroxidase-coupled secondary antibody. The protein bands
were visualized with chemiluminescence (ECL) (PerkinElmer) and detected by Image Quant LAS 4000 (GE Health care Life Sciences). The rabbit anti-human HMGA2 polyclonal antibody was purchased from Bio Check, Inc. Other antibodies (β-actin, vimentin and β-catenin) were purchased from Cell signaling Technology.

Clonogenic assay

Single-cell suspensions were generated for each cell line and specified numbers of cells (100) were seeded into six-well tissue culture plates. Cells were cultured for 10-14 days, stained with 0.01% crystal violet and colonies with greater than 50 cells were counted.

MTT assay

Cell proliferation was measured using 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded into 96-well plates (1.0-2.0×10^3 cells/well) and cultured for 1-5 days. At specified time points, 20 μl of MTT (Sigma-Aldrich) solution (0.5 mg/ml) was added to each well, and the cells were incubated for additional 4 hours at 37°C. Then the supernatants were carefully removed and 100 μl of dimethyl sulfoxide (DMSO, Sigma-Aldrich) was added to each well. The absorbance values were evaluated at 490 nm with a Microplate Reader (Thermo Fisher Scientific).

Immunohistochemistry

Formalin-fixed and paraffin-embedded tissues were sectioned at 4 μm. The slides were deparaffinized in xylene and rehydrated in a graded series of ethanol. Antigen retrieval was performed by microwave irradiation in EDTA retrieval solution (PH 8.0). The Endogenous peroxidase activity was blocked by 3% hydrogen peroxidase (SIGMA-ALDRICH; #216763) in methanol. The slides were then incubated over night at 4°C with HMGA2 (anti-rabbit, BioCheck, Inc) primary antibody at 1:900 dilution. The following steps were performed by Vectastain ABC kit (Rabbit IgG, Vector, PK4001) according to manufacturer's instruction. The signal was developed by DAB detection system and negative immunohistochemistry controls were routinely employed. The staining results were scored semiquantitatively by extent and intensity.

RNA isolation and qRT-PCR

Total RNA was extracted from endometrial cancer cells using TRIzol Reagent (Ambion) following manufacturer's instructions. The cDNA was synthesized from miRNA using the One Step PrimeScript miRNA cDNA Synthesis Kit (Takara). Quantitative real-time PCR was performed by StepOne Plus Real-Time PCR System (Applied Biosystems) with SYBR green Premix Ex Taq II (Takara). The expression of GAPDH was used as the endogenous control for miRNA expression level.

Subcutaneous tumor implantation and tail-vein injections in nude mice

SPEC-2 cells with either overexpression or normal control of HMGA2 (normal control: empty vector) were injected subcutaneously into the bilateral flanks of 4-6-week-old female BALB/c nu/nu mice. About 5×10^6 cells were resuspended in 120 μl of solution mixture containing PBS and Matrigel (5:1, BD falcon). Size of tumors were measured weekly, and mice were euthanized when tumors reached 2.0 cm in diameter. The tumor volume were calculated using the equation a×b^2×π/6, where “a” and “b” are the longest and shortest diameter, respectively. Tail-vein injection experiments were performed on 4-6-week-old BALB/c nu/nu female mice by injecting 1×10^6 cells suspended in 100 μl of PBS into the lateral tail veins. Ten weeks later, the lungs were collected and fixed in 4% formalin. All animal experiments were performed with the approval of Shandong University Animal Care and Use Committee.

Trp53 knockout mice model

Trp53^fl/fl mice (B6.129P2-Trp53tm1Brn/J) and Ksp1.3-Cre mice (B6.Cg-Tg (Cdh16-cre) 91ig/j) were purchased from the Jackson Laboratory to generate +/+; Trp53^fl/fl (Wild Type) and Ksp1.3-Cre/+; Trp53^fl/fl (hereafter referred to as Trp53^∆/∆) mice [16]. Exons 2-10 of Trp53 gene, the mouse homologue of human TP53, were flanked by loxP in this conditional targeted knockout. Genotyping of the Trp53 allele and Ksp1.3-Cre was performed by PCR-based test using the following primer pairs for Trp53 (5’-GGTTAAACCCAGCTTGACCA-3’ and 5’-GGAGGCAGAGACAGTGGAGGAG-3’) and for Ksp1.3-Cre (5’-GCAGATCTGGCTCTCCAAAG-3’ and 5’-AGGAGGACAGAGACAGTGGAGGAG-3’).
HMGA2 expression in non-neoplastic endometrial tissues

HMGA2 is rarely detected within normal adult tissues, but is expressed by a variety of benign and malignant tumors [7, 11, 17]. To evaluate whether HMGA2 is overexpressed in non-neoplastic endometrial tissues, we immunohistochemically examined HMGA2 expression in benign endometrium samples (n=28). We found that most of the benign endometrium samples showed negative expression of HMGA2. Only two cases were positive with one focal staining of a single weakly proliferative endometrial gland and one occasional staining (Figure 1A-C) has any biologic meaning.

Results

HMGA2 expression in non-neoplastic endometrial tissues

The statistical analysis was carried out using SPSS V20.0. Student’s t-test was applied to analyze the statistical differences. All the experiments were repeated for at least three times. Significance levels were "p<0.05; \(^{**}p<0.001."

Figure 1. Photomicrographs illustrate some examples of intensity of HMGA2 expression in benign endometrium, endometrial serous carcinomas (ESCs) and their precursor lesions. A-C. HMGA2 expression in cases of benign endometrium. D. Immunohistochemical and hematoxylin and eosin (H/E) staining on serous endometrial glandular dysplasia (EmGD). E. Immunohistochemical and hematoxylin and eosin (H/E) staining on serous endometrial intraepithelial carcinoma (EIC). F. Immunohistochemical and hematoxylin and eosin (H/E) staining on endometrial serous carcinoma (ESC). Scale bars=50 μm.
HMGA2 in endometrial serous carcinogenesis

Table 1. HMGA2 immunoreactivity in benign endometrium and neoplastic endometrium

<table>
<thead>
<tr>
<th>Extent tissue staining</th>
<th>Case/Foci assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>80%-100%</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>50%-79%</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>25%-49%</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>&lt;25%</td>
<td>2 (7.1%)</td>
</tr>
<tr>
<td>0%</td>
<td>26 (92.9%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Benign endometrium</th>
<th>28</th>
<th>0 (0%)</th>
<th>0 (0%)</th>
<th>0 (0%)</th>
<th>2 (7.1%)</th>
<th>26 (92.9%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Precursor and noninvasive lesions</td>
<td>17</td>
<td>1 (5.9%)</td>
<td>6 (35.3%)</td>
<td>1 (5.9%)</td>
<td>4 (23.5%)</td>
<td>5 (29.4%)</td>
</tr>
<tr>
<td>Serous EmGD</td>
<td>8</td>
<td>1 (12.5%)</td>
<td>4 (50%)</td>
<td>0 (0%)</td>
<td>2 (25%)</td>
<td>1 (12.5%)</td>
</tr>
<tr>
<td>Serous EIC</td>
<td>8</td>
<td>1 (12.5%)</td>
<td>4 (50%)</td>
<td>0 (0%)</td>
<td>2 (25%)</td>
<td>1 (12.5%)</td>
</tr>
<tr>
<td>Endometrial cancers</td>
<td>61</td>
<td>6 (9.8%)</td>
<td>12 (19.7%)</td>
<td>2 (3.3%)</td>
<td>7 (11.5%)</td>
<td>34 (55.7%)</td>
</tr>
<tr>
<td>Endometrioid</td>
<td>61</td>
<td>6 (9.8%)</td>
<td>12 (19.7%)</td>
<td>2 (3.3%)</td>
<td>7 (11.5%)</td>
<td>34 (55.7%)</td>
</tr>
<tr>
<td>Serous</td>
<td>59</td>
<td>16 (27.1%)</td>
<td>23 (39.0%)</td>
<td>2 (3.4%)</td>
<td>11 (18.6%)</td>
<td>7 (11.9%)</td>
</tr>
</tbody>
</table>

| Intensity of the immunoreactivity | Strong | Moderate | Weak | Absent | |
|----------------------------------|--------|----------|------|--------|
| Benign endometrium | 28 | 0 (0%) | 1 (3.6%) | 1 (3.6%) | 26 (92.9%) |
| Precursor and noninvasive lesions | 17 | 2 (11.8%) | 7 (41.2%) | 3 (17.6%) | 5 (29.4%) |
| Serous EmGD | 8 | 1 (12.5%) | 5 (62.5%) | 1 (12.5%) | 1 (12.5%) |
| Serous EIC | 8 | 1 (12.5%) | 5 (62.5%) | 1 (12.5%) | 1 (12.5%) |
| Endometrial cancers | 61 | 0 (0%) | 19 (31.1%) | 8 (13.1%) | 34 (55.7%) |
| Endometrioid | 61 | 0 (0%) | 19 (31.1%) | 8 (13.1%) | 34 (55.7%) |
| Serous | 59 | 15 (25.4%) | 29 (49.2%) | 8 (13.6%) | 7 (11.9%) |

HMGA2 expression in endometrial cancer and its precursor lesions

We next evaluated HMGA2 expression in endometrial glandular dysplasia (EmGD, n=17), serous endometrial intraepithelial carcinomas (SEIC, n=8), endometrial serous carcinomas (ESC, n=59), endometrial endometrioid carcinomas (EEC, n=61). As shown in Figure 1D-F and Table 1, EmGD and SEIC exhibited a significantly higher rate of HMGA2 expression. Among the 17 cases of EmGD, 1 was diffusely positive (80-100% of the cells), 6 with 50-79% positive cells, 1 with focal staining (25-50% positive cells) and 4 with less than 25% positive cells. In the SEIC category, 7 of 8 were positive with 1 being diffuse, 4 with 50-79%, and 2 with <25% positive cells. Most of these SEICs showed moderate and strong staining intensity. Similar to SEIC, the expression of HMGA2 in ESC was obvious and diffuse. If positivity for HMGA2 is defined as ≥50% staining, irrespective of intensity of staining, it showed an increased level of expression from EmGD (7 of 17, 41.2%) to SEICs (5 of 8, 62.5%) and to ESC (39 of 59, 66.1%). In contrast to type II endometrial carcinomas, EECs exhibited a significantly lower rate of HMGA2 expression. From the 61 EECs, 34 (55.7%) showed complete negative and 9 (14.8%) showed HMGA2 positive in less than 50% endometrial glandular epithelial cells. The positive rate for HMGA2 in EECs was 29.5%. These results suggest that most HMGA2 overexpression was related to the endometrial serous carcinogenesis, rather than the development of EECs.

Endometrial cancer cell lines increased proliferation after HMGA2 overexpression in vitro

To investigate whether HMGA2 play an oncogenic role in endometrial carcinoma, we measured HMGA2 baseline expression in six endometrial cancer cell lines by real-time PCR (Figure 2A). Given that HMGA2 was relatively low expression in SPEC-2 cells, which were derived from ESC, we selected the cell line generating HMGA2 overexpressed cells by transfecting HMGA2 overexpression plasmid. Expression efficiency was validated by RT-PCR and Western blot (Figure 2B and 2C). We then measured the effect of HMGA2 on endometrial cancer cells proliferation by clonogenic assay. As shown in Figure 2D, overexpression of HMGA2 significantly promoted colony-forming efficiency of the endometrial cancer cells. The effect of HMGA2 on endometrial cancer cell proliferation was further confirmed by MTT assay. HMGA2 overexpression significantly enhanced endometrial cancer cells growth when compared to the control cells.
Endometrial cancer cell increased ability of migration and invasion after HMGA2 overexpression

To investigate whether HMGA2 overexpression promotes migration and invasion of endometrial cancer cells in vitro, we first performed HMGA2 siRNA knockdown experiments. As shown in Figure 3A, HMGA2 repression by siRNAs in Ishikawa cells was measured by Western blot. We then examined the expression of EMT markers by Western blot in SPEC-2 cells with and without HMGA2 overexpression. As shown in Figure 3B, HMGA2 overexpression increased the levels of vimentin and β-catenin. We further performed in vitro invasion and migration by transwell assay. As demonstrated in Figure 3C, we observed a significant increase in both migration and invasion in SPEC-2 cells with HMGA2 overexpression. We also performed transwell assay in HMGA2 knockdown Ishikawa cells. Compared with the control cells, HMGA2 knockdown cells exhibited reduced migration and invasion (Figure 3D). These results suggested that HMGA2 promotes migration and invasion of endometrial cancer cells through inducing EMT.

HMGA2 promoted tumor growth and metastasis in xenografts

To determine whether HMGA2 could affect tumorigenesis in vivo, SPEC-2 cells with and without HMGA2 overexpression were subcutaneously inoculated into nude mice (n=9 for each group). As demonstrated in Figure 4A, tumor sizes derived from HMGA2 overexpressed cells were bigger than those in the control group. We further performed in vivo metastasis analysis via tail vein injection. SPEC-2 cells with and without HMGA2 overexpression were injected into nude mice via tail
After 8 weeks mice were anesthetized and mouse lungs were harvested, fixed and dissected. Five of six mice transplanted with SPEC-2-HMGA2 cells had pulmonary metastasis loci and two of the five had visible metastatic nodules, while two of six mice transplanted with SPEC-2-NC cells had pulmonary metastasis loci and no mouse of the five had visible metastatic nodules (Figure 4B). These results suggest that overexpression of HMGA2 promotes tumor growth and metastasis in vivo.

**Figure 3.** HMGA2 promote migration and invasion of endometrial cancer cells in vitro. A. HMGA2 repression by siRNAs in ishikawa cells was measured by Western blot. B. Western blot analysis confirmed MET related markers showed different expression in SPEC-2 cells with and without HMGA2 overexpression. C. Migration and invasion were measured by transwell assay in SPEC-2 cell lines with and without HMGA2 overexpression. D. Migration and invasion were performed in ishikawa cells with and without HMGA2 depletion by siRNA-2#. *P<0.05, **P<0.01.
HMGA2 in endometrial serous carcinogenesis

Discussion

HMGA2 is abundantly expressed during embryogenesis, but it is either undetectable or its expression remains at low levels in normal adult tissues [18]. Interestingly, HMGA2 is highly expressed in most malignant epithelial tumors [19]. Overexpression of HMGA2 is found to be an early-stage biomarker in High-grade serous ovarian carcinoma [13]. In this study, we have demonstrated that HMGA2 expression was detected occasionally in benign endometrium samples (2 of 28 samples). HMGA2-positive normal appearing endometrial epithelia may be an early event in the pathogenesis of endometrial serous carcinoma. Importantly, overexpression of HMGA2 show-
ed an increased pattern from serous EmGDs (7 of 17, 41.2%) to serous EICs (5 of 8, 62.5%) and to ESCs (39 of 59, 66.1%). HMGA2 positivity in EmGDs and EICs suggest that it is implicated in the early development of endometrial serous carcinoma.

Our results are concordant a previous study [14], which indicated that HMGA2 was overexpressed in more than 50% of endometrial serous carcinomas. HMGA2 may play an oncogenic role in tumorigenesis and progression of endometrial serous carcinoma. The oncogenic
properties of HMGA2 are reported to be involved in tumor transformation [20], tumor growth [21] and tumor metastasis [22]. We investigated the oncogenic properties of HMGA2 in endometrial cancer cells through in vitro and in vivo study. We found overexpression of HMGA2 in endometrial cancer cells significantly promoted proliferation, migration and invasion in vitro and enhanced tumor growth and metastasis in vivo. Importantly, HMGA2 induced epithelial-mesenchymal transition (EMT) through modulation vimentin and β-catenin.

HMGA2 overexpression was reported to associate with p53-dominant mutations in high-grade ovarian serous carcinoma [12]. Our previous study showed alteration of p53 is an early event in the development of endometrial serous carcinoma [23]. In Trp53 knockout mouse model, HMGA2 became overexpression even from morphologically benign endometrium. HMGA2 may be another useful early-stage diagnostic marker of ESCs. Future studies are needed to elucidate the relationship and mechanism between P53 and HMGA2.

In summary, our results in this study suggest that HMGA2 overexpression is closely associated with endometrial serous cancer. HMGA2 may serve as a useful diagnostic marker in the assessment of endometrial cancers and their precursor lesions. We further demonstrated that HMGA2 overexpression is closely associated with tumor growth and metastasis. Importantly HMGA2 induced epithelial-mesenchymal transition (EMT) of endometrial cancer cells. Future studies are needed to assess the correlations between HMGA2 and clinicopathologic features and prognosis.

Acknowledgements

This study was partially supported by awards from National 863 Program (2014AA020605), and The National Natural Science Foundation of China (81472432, 81272857, 81171897).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Beihua Kong, Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan 250012, Shandong Province, China. Tel: 86-531-82169269; Fax: 86-531-82169268; E-mail: kongbeihua@sdu.edu.cn; Dr. Wenxin Zheng, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Tel: 214-648-1190; E-mail: Wenxin.Zheng@UTSouthwestern.edu; Dr. Zhaojian Liu, Department of Cell Biology, Shandong University School of Medicine, 44 Wenhua Xi Road, Jinan 250012, Shandong Province, China. Tel: 86-531-88382046; Fax: 86-531-88382021; E-mail: liujian9782@sdu.edu.cn

References

HMGA2 in endometrial serous carcinogenesis


